Scientific communications

In its commitment to enable drug candidate testing in a cost-saving way, Explicyte is launching an upcoming in vivo shuttle session thus providing an opportunity to speed up your cancer therapy discovery process.

Using a syngeneic MCA205 sarcoma tumor model – widely used for the evaluation of innovative cancer immunotherapies – we investigated the anti-tumor activity of several combination therapies. This model is known to be responsive to PD1/PDL1 axis blockade but only partially to anti-CTLA4 antibody. Interestingly, while an additive benefit of anti-PD1 and anti-PDL1 is observed, a clear synergistic effect is achieved upon combination of either anti-PD1 or anti-PDL1 with anti-CTLA4, with a full tumor rejection in all treated animals.

Spotlight on the immunomodulatory and anti-tumor activities of Temozolomide

Glioblastoma (GBM) is the most common malignant adult brain tumor. Despite the multimodality of treatment strategies including surgery, radiotherapy and chemotherapy, with a standard of care being temozolomide (TMZ) in combination with radiotherapy, the prognosis of GBM patients is still dismal, and the need to develop and assess novel combinatorial strategies remains critical.

Take advantage of new available seats on board or our upcoming shuttle session, scheduled by early May, to cost-effectively run your candidates on our robust M2 macrophage polarization assaythereby saving up to 25% full cost.

Digital pathology for tumor immune infiltrate analysis and patient selection
To assess whether or not the tumor immune contexture was predictive of response to the Avelumab-Regorafenib combination regimen, Explicyte developed and ran, on baseline FFPE samples, a multiplexed immunohistofluorescence panel consisting of CD8, PD1, PDL1, CD163, IDO1, and PanKeratin markers, in addition to Dapi (Discovery XT, Roche Diagnostics).

Explicyte is planning a new cost-effective in vivo shuttle session by end of February and thus provides an opportunity to speed up your new cancer therapy discovery process.

It therefore becomes primordial to benefit from a technological platform that allows to deal with the tumor biology complexity/heterogeneity and get specific investigations in compartments of interest (e.g. tumor vs stroma). Thanks to the GeoMx platform (Nanostring Inc.), which combines the spatial resolution of immunohistofluorescence with the high-plex gene/protein expression analysis, the Digital Spatial Profiling (DSP) revolution has started.

We have fully set up and characterized a syngeneic Renca renal mouse model recapitulating most of the human RCC condition features. Indeed, our model displays an enriched tumor microvascular environment and relatively low immune infiltration - nevertheless constituted of a strong Myeloid-Derived Suppressor Cells (MDSCs) proportion.

To deal with the current challenge of a qualitative and quantitative tumor immune landscape characterization, we have set up a fully integrated platform spanning from FFPE slide preparation and staining, to image digitization and analysis.

Explicyte is indeed planning a new in vivo shuttle session by mid-October, to be held on a series of syngeneic tumor-bearing mouse models such as MCA025 sarcoma, 4T1 & EMT6 breast cancer, MC38 & CT26 colon cancer or Renca renal cancer, among others.